NCT05702684 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Carroll K, Mesman J
Multiple Researcher Roles in Video-Reflexive Ethnography. Qual Health Res. 2018 Jun;28(7):1145-1156. doi: 10.1177/1049732318759490. Epub 2018 Feb 24.
Iedema R
Research paradigm that tackles the complexity of in situ care: video reflexivity. BMJ Qual Saf. 2019 Feb;28(2):89-90. doi: 10.1136/bmjqs-2018-008778. Epub 2018 Oct 11. No abstract available.
Iedema RA, Angell B
What are patients' care experience priorities? BMJ Qual Saf. 2015 Jun;24(6):356-9. doi: 10.1136/bmjqs-2015-004298. Epub 2015 May 13. No abstract available.
Varpio L, Ajjawi R, Monrouxe LV, O'Brien BC, Rees CE
Shedding the cobra effect: problematising thematic emergence, triangulation, saturation and member checking. Med Educ. 2017 Jan;51(1):40-50. doi: 10.1111/medu.13124.
Wyer M, Jackson D, Iedema R, Hor SY, Gilbert GL, Jorm C, Hooker C, O'Sullivan MV, Carroll K
Involving patients in understanding hospital infection control using visual methods. J Clin Nurs. 2015 Jun;24(11-12):1718-29. doi: 10.1111/jocn.12779. Epub 2015 Feb 7.

Coproducing Personalised Care in a Digital Age: Using the Adversity, Restoration and Compatibility (ARC) Framework to Inform the Co-design of a Digital Care Planning Tool for People With Colorectal Cancer.

Details for clinical trial NCT05702684

Clinical trial NCT05702684 - References